medigraphic.com
Colegio de Medicina Interna de México.

2016, Number 2

<< Back Next >>

Med Int Mex 2016; 32 (2)

Association between severity of plaque psoriasis and metabolic syndrome

Valdés-Solís E, Colorado-García LM, Lozano-Nuevo JJ, Rubio-Guerra F

Language: Spanish
References: 48
Page: 190-200
PDF size: 730.42 Kb.


ABSTRACT

Background: With a better understanding of the pathogenesis of psoriasis, it is no longer an exclusively cutaneous disease but a chronic inflammatory disease with systemic manifestations. Numerous comorbidities associated with psoriasis have been described, including a higher prevalence of metabolic syndrome and cardiovascular risk factors, arthropathy, increased consumption of snuff and alcohol, psychological manifestations and impaired quality of life.
Objetive: To evaluate the association of metabolic syndrome with severe psoriasis.
Material and Method: A cross-sectional, analytic study in patients with severe psoriasis of the Xoco General Hospital, Mexico City. Demographics and characteristics of plaque psoriasis (evolution time, family history, severity and treatment), presence of comorbidities and treatment (history of hypertension, diabetes, dyslipidemia) waist-hip ratio, body mass index were determined, as well as analytical results (glucose, cholesterol, triglycerides) and toxic habits (smoking and alcohol).
Results: 132 patients (60% men and 40% women), aged between 18 and 55 years, were included. We found a high prevalence of overweight and obesity (72.71%) and criteria for metabolic syndrome in 37% of patients, with no difference between men and women. We found statistical relationship between metabolic syndrome and psoriasis severity (p=0.001), alcohol consumption (p= 0.001) and type of treatment of psoriasis (p=0.001).
Conclusion: We found a high prevalence of metabolic syndrome and each of its components, especially obesity, with important relationship of this syndrome with the severity and treatment of psoriasis.


REFERENCES

  1. Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl 2012;89:24-28. doi:10.3899/jrheum.120237.

  2. Bell LM, Sedlack R, Beard CM, Perry H, et al. Incidence of psoriasis in Rochester, Minn., 1980-1983. Arch Dermatol 1991;127:1184-1187.

  3. Vena GA, Altomare G, Ayala F, Berardesca E, et al. Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Eur J Dermatol 2010;20:593-598.

  4. Jurado SCF y col. Psoriasis y síndrome metabólico. Rev Cent Dermatol Pascua 2013;22.

  5. Lebwohl M. Psoriasis. Lancet 2003;361:1197-1204.

  6. Ferrándiz C, Pujol RM, García-Patos V, Bordas X, Smandía JA. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002;46:867-873.

  7. Kaur I, Handa S, Kumar B. Natural history of psoriasis: a study form Indian subcontinent. J Dermatol 2007;24:230-234.

  8. Andressen C, Henseler T. Inheritance of psoriasis. Analysis of 2035 family histories. Hautzarzt 2002;33:214-217.

  9. Nair RP, Stuart PE, Nistor I, Hiremagalore R, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2008;78:827-851.

  10. Trembath RC, Clough RL, Rosbotham JL, Jones AB, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 2009;6:813-820.

  11. Mallon E, Newson R, Bunker CB. HLA-Cw6 and the genetic predisposition to psoriasis: a meta-analysis of published serologic studies. J Invest Dermatol 1999;113:693-695.

  12. Duffy DL, Spelman LS, Martin NG. Psoriasis in Australian twins. J Am Acad Dermatol 1993;29:428-434.

  13. Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, Kristinsson KG, Valdimarsson H. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol 2003;149:530-534.

  14. Leal L, Ribera M, Daudén E. Psoriasis e infección por el virus de la inmunodeficiencia humana. Actas Dermosifiliogr 2008;99:753-763.

  15. Picardi A, Mazzotti E, Gaetano P, Cattaruzza MS, et al. Stress, social support, emocional regulation, and exacerbation of diffuse plaque psoriasis. Psychosomatics 2005;46:556-564.

  16. Schmid-Ott G, Jaeger B, Boehm T, Langer K, et al. Immunological effects of stress in psoriasis. Br J Dermatol 2009;160:782-785.

  17. Michaëlsson G, Gustafsson K, Hagforsen E. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol 2006;54:737-738.

  18. Gerdes S, Zahl VA, Weichenthal M, Mrowietz U. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 2010;220:38-43.

  19. Daudén E, Castañeda S, Suárez C, García-Campayo J, et al. Integrated approach to comorbidity in patients with psoriasis. Working Group on Psoriasis-Associated Comorbidities. Actas Dermosifiliogr 2012;103:1-64.

  20. Wolters M. Diet and psoriasis: experimental data and clinical evidence. Br J Dermatol 2005;153:706-714.

  21. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol 2010;49:1351-1361.

  22. Morell L, Carrascosa JM, Ferrándiz C, García-Bustinduy M, et al. Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study. Actas Dermosifiliogr 2011;102:354-364.

  23. Camargo CM, Brotas AM, Ramos-e-Silva M, Carneiro S. Isomorphic phenomenon of Koebner: facts and controversies. Clin Dermatol 2013;31:741-749.

  24. Attwa E, Swelam E. Relationship between smokinginduced oxidative stress and the clinical severity of psoriasis. J Eur Acad Dermatol Venereol 2011;25:782-787.doi: 10.1111/j.1468-3083.2010.03860.x.

  25. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009;129:1339-1350.

  26. Ghoreschi K, Weigert C, Röcken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007;25:574- 580.

  27. Nograles KE, Davidovici B, Krueger JG. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg 2010;29:3-9.

  28. Griffiths CE, Barker JN. Psoriasis 1: pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-271.

  29. Cantini F, Niccoli L, Nannini C, Kaloudi O, et al. Psoriasis arthritis: a systematic review. Int J Rheum Dis 2010;13:300- 317.

  30. Syed ZU, Khachemoune A. Inverse psoriasis: case presentation and review. Am J Clin Dermatol 2011;12:143-146.

  31. Baran R. The burden of nail psoriasis: an introduction. Dermatology 2010;221:1-5.

  32. Zeichner JA, Lebwohl MG, Menter A, Bagel J, et al. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis 2010;86:5-31.

  33. Fonseca E, Paradela S, Rodríguez Lozano J, Fernández Torres R. Guías para el tratamiento de la psoriasis en placas moderada-grave con terapias biológicas. En: Fonseca E. Terapias biológicas para la psoriasis. Madrid, 2009:117-136.

  34. Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther 2010;23:114-118.

  35. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013;8:4-6.

  36. Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL. Metabolic syndrome and risks of subsequent colorectal cancer. World J Gastroenterol 2009;15:5141-5148.

  37. Arias-Santiago S, Orgaz-Molina J, Castellote-Caballero L, Arrabal-Polo MA, et al. Atheroma plaque, metabolic syndrome and inflammation in patients with psoriasis. Eur J Dermatol 2012;22:337-344.

  38. Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol 2010;90:23-26.

  39. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus. A systematic review and meta-analysis. Arch Dermatol 2012:1-8. doi: 10.1001/2013. jamadermatol.406.

  40. Espinola-Klein C, Gori T, Blankenberg S, Munzel T. Inflammatory markers and cardiovascular risk in the metabolic syndrome. Front Biosci 2011;16:1663-1674.

  41. Shibata S, Tada Y, Hau C, Tatsuta A, et al. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol 2011;164:667-670.

  42. Mehta NN, Azfar RS, Shin DB, Neimann AL, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010;31:1000-1006.

  43. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based study in the United Kingdom. Arch Dermatol 2003;139:1425-1429.

  44. Hayes J, Koo J. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther 2010;23:174-180.

  45. Bronsard V, Paul C, Prey S, Puzenat E, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010;24:17-22.

  46. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009;60(2):218- 224. doi: 10.1016/j

  47. Ferrándiz C, Carrascosa JM, Boada A. A new era in the management of psoriasis? The biologics: facts and controversies. Clin Dermatol 2010;28:81-87. doi: 10.1016.

  48. Mak RK, Hundhausen C, Nestle FO. Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr 2009;100:2-13. AVISO PARA LOS AUTORES




2020     |     www.medigraphic.com